These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32140806)

  • 21. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
    Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
    Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
    Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
    Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Royal College of General Practitioners' Oral Contraception Study: some recent observations.
    Kay CR
    Clin Obstet Gynaecol; 1984 Dec; 11(3):759-86. PubMed ID: 6509858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral contraceptive use and BRCA penetrance: a case-only study.
    Pasanisi P; Hédelin G; Berrino J; Chang-Claude J; Hermann S; Steel M; Haites N; Hart J; Peled R; Gafà L; Leggio L; Traina A; Amodio R; Primic-Zakelj M; Zadnik V; Veidebaum T; Tekkel M; Berrino F
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2107-13. PubMed ID: 19549808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients.
    Iatrakis G; Iavazzo C; Zervoudis S; Koumousidis A; Sofoudis C; Kalampokas T; Salakos N
    Clin Exp Obstet Gynecol; 2011; 38(3):225-7. PubMed ID: 21995151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoplasia and hormonal contraception.
    Huggins GR
    Clin Obstet Gynecol; 1981 Sep; 24(3):903-25. PubMed ID: 7026111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
    Iodice S; Barile M; Rotmensz N; Feroce I; Bonanni B; Radice P; Bernard L; Maisonneuve P; Gandini S
    Eur J Cancer; 2010 Aug; 46(12):2275-84. PubMed ID: 20537530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    Brohet RM; Goldgar DE; Easton DF; Antoniou AC; Andrieu N; Chang-Claude J; Peock S; Eeles RA; Cook M; Chu C; Noguès C; Lasset C; Berthet P; Meijers-Heijboer H; Gerdes AM; Olsson H; Caldes T; van Leeuwen FE; Rookus MA
    J Clin Oncol; 2007 Sep; 25(25):3831-6. PubMed ID: 17635951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoplastic effects of oral contraceptives.
    Grimes DA
    Int J Fertil; 1991; 36 Suppl 1():19-24. PubMed ID: 1678377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.
    Henningson M; Johansson U; Borg A; Olsson H; Jernström H
    Mol Hum Reprod; 2007 Apr; 13(4):231-6. PubMed ID: 17307805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
    Antoniou AC; Rookus M; Andrieu N; Brohet R; Chang-Claude J; Peock S; Cook M; Evans DG; Eeles R; ; Nogues C; Faivre L; Gesta P; ; van Leeuwen FE; Ausems MG; Osorio A; ; Caldes T; Simard J; Lubinski J; Gerdes AM; Olah E; Fürhauser C; Olsson H; Arver B; Radice P; Easton DF; Goldgar DE
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):601-10. PubMed ID: 19190154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance.
    Grandi G; Fiocchi F; Cortesi L; Toss A; Boselli F; Sammarini M; Sighinolfi G; Facchinetti F
    Menopause; 2021 Nov; 29(1):63-72. PubMed ID: 34726192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral contraceptives and breast cancer: review of the epidemiologic literature.
    Thomas DB
    Contraception; 1991 Jun; 43(6):597-642. PubMed ID: 1868735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
    BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer.
    Tea MK; Kroiss R; Muhr D; Fuerhauser-Rappaport C; Oefner P; Wagner TM; Singer CF
    Maturitas; 2014 Jan; 77(1):68-72. PubMed ID: 24156927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
    Khoo SK; Chick P
    Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer risks and the contraceptive pill. What is the evidence after nearly 25 years of use?
    Khoo SK
    Med J Aust; 1986 Feb; 144(4):185-90. PubMed ID: 3511357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.